Addressing the Impact of ACI: Innovating Therapeutic Solutions for Cannabinoid Intoxication |Simon Allen, CEO, Anebulo Pharmaceuticals Inc. 00:10:00
The podcast episode features Simon Allen, CEO of a pharmaceutical company, discussing their efforts to develop a treatment for acute cannabinoid intoxication (ACI). Simon highlights the challenges posed by the growing use of cannabis products, particularly synthetic cannabinoids, and their lead candidate, "007," which targets the CB1 receptor to mitigate ACI symptoms. He emphasizes the urgent need for FDA-approved treatments and their progress in clinical trials to provide a safer option for patients.
